繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 抗感染类 >> 药品目录 >> 抗生素类 >> 头孢菌素类 >> AVYCAZ for Injection(ceftazidime/avibactam)

AVYCAZ for Injection(ceftazidime/avibactam)

2016-07-06 09:12:13  作者:新特药房  来源:互联网  浏览次数:3  文字大小:【】【】【
简介: Avycaz(ceftazidime-avibactam)是一种新型抗生素/固定剂量的复方药物,Avycaz与甲硝唑联合用于治疗复杂性腹腔内感染 (cIAI) 及复杂性尿路感染 (cUTI) 成人患者,其中包括肾脏感染(肾盂肾炎),适用于治 ...

Avycaz(ceftazidime-avibactam)是一种新型抗生素/固定剂量的复方药物,Avycaz与甲硝唑联合用于治疗复杂性腹腔内感染 (cIAI) 及复杂性尿路感染 (cUTI) 成人患者,其中包括肾脏感染(肾盂肾炎),适用于治疗选择有限或没有替代治疗选择的患者。
商标名称:Avycaz
通用名称:avibactam和头孢他啶
治疗:腹腔感染时,尿路感染
推荐剂量
在18岁和以上患者中AVYCAZ的推荐剂量是每8小时2.5克(2克头孢他啶和0.5克avibactam)通过历时2小时静脉(IV)输注给予。对cIAI的治疗,应同时地给予甲硝唑。表1中列出了在有正常肾功能患者中对AVYCAZ剂量的指导原则。
给药AVYCAZ溶液的制备
AVYCAZ以干粉提供,静脉输注前用无菌术干粉必须被重建和随后被稀释。
a)在AVYCAZ小瓶用以下溶液之一10 mL重建粉:
● 无菌注射用水,USP
● 0.9%氯化钠注射液,USP(生理盐水)
● 5%的葡萄糖注射液,USP
● 葡萄糖注射液和氯化钠注射液,USP的所有组合,含直至2.5%葡萄糖,USP,和0.45% 氯化钠,USP,或
● 乳酸林格氏注射液,USP)
b)轻轻混合。重建的AVYCAZ溶液将有一个约头孢他啶浓度0.167克/mL和一个约avibactam 浓度0.042克/mL。
c)用为重建粉相同稀释液(除了注射用无菌水),输注前稀释重建的AVYCAZ溶液进一步实现总容积在50mL(头孢他啶和avibactam分别40和10mg/mL)至250mL(头孢他啶和avibactam分别8和2mg/mL)间。
d)轻轻混合和确保内容物被完全溶解。给药前肉眼观察被稀释的AVYCAZ溶液(为给药)颗粒物质和变色(为给药AVYCAZ输注溶液的颜色范围从清澈至淡黄色)。
e) 在室温贮存在12小时内使用输注袋中已稀释的AVYCAZ溶液。在输注袋中稀释的AVYCAZ溶液在冰箱2至8°C(36至46°F)在稀释后可被贮存至24小时和随后在室温贮存12小时内。


AVYCAZ(AVIBACTAM SODIUM CEFTAZIDIME)POWDER IV (INFUSION)
Avycaz (ceftazidime-avibactam) is a combination of a cephalosporin and a beta-lactamase inhibitor.
Avycaz in combination with metronidazole, is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Providencia stuartii, Enterobacter cloacae, Klebsiella oxytoca, and Pseudomonas aeruginosa in patients 18 years or older.
Avycaz is also indicated for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter koseri, Enterobacter aerogenes, Enterobacter cloacae, Citrobacter freundii, Proteus spp., and Pseudomonas aeruginosa in patients 18 years or older.
Avycaz is supplied as a solution for intravenous infusion. The recommended dosage of Avycaz is 2.5 grams (2 grams ceftazidime and 0.5 grams avibactam) administered every 8 hours by intravenous (IV) infusion over 2 hours. For treatment of cIAI, metronidazole should be given concurrently.
Avycaz(avibactam/ceftazidime)
THERAPEUTIC CLASS
Beta-lactamase inhibitor/cephalosporin
DEA CLASS
RX
ADULT DOSAGE & INDICATIONS
Intra-Abdominal Infections
Complicated Infections:
2.5g (2g/0.5g) IV q8h for 5-14 days in combination w/ metronidazole
Urinary Tract Infections
Complicated Infections, Including Pyelonephritis:
2.5g (2g/0.5g) IV q8h for 7-14 days
DOSING CONSIDERATIONS
Renal Impairment
CrCl 31-50mL/min: 1.25g (1g/0.25g) IV q8h
CrCl 16-30mL/min: 0.94g (0.75g/0.19g) IV q12h
CrCl 6-15mL/min: 0.94g (0.75g/0.19g) IV q24h
CrCl ≤5mL/min: 0.94g (0.75g/0.19g) IV q48h
Administer after hemodialysis on hemodialysis days
For patients w/ changing renal function, monitor CrCl at least daily and adjust the dose accordingly
ADMINISTRATION
IV route
Administer by IV infusion over 2 hrs.
Preparation of Sol for Administration
1. Constitute powder in the vial w/ 10mL of 1 of the following sol: sterile water for inj (SWFI); 0.9% NaCl inj; D5 inj; all combinations of dextrose inj and NaCl inj, containing up to 2.5% dextrose, and 0.45% NaCl; or lactated Ringer's inj.
2. Mix gently; constituted sol will have an approx ceftazidime level of 0.167g/mL and an approx avibactam level of 0.042g/mL. The constituted sol is not for direct injection; must be diluted before IV infusion.
3. Prepare the required dose for IV infusion by withdrawing the appropriate volume from the constituted vial; refer to PI for volume to withdraw.
4. Before infusion, dilute the withdrawn volume of the constituted sol further w/ the same diluent used for constitution of the powder (except SWFI), to achieve total volume between 50mL (0.04g/mL ceftazidime and 0.01g/mL avibactam) to 250mL (0.008g/mL ceftazidime and 0.002g/mL avibactam) in an infusion bag. If SWFI was used for constitution, use any of the other appropriate constitution diluents for dilution.
5. Mix gently and ensure contents are dissolved completely.
Drug Compatibility
The sol for administration at the range of diluted concentrations of ceftazidime 0.008g/mL and avibactam 0.002g/mL to ceftazidime 0.04g/mL and avibactam 0.01g/mL is compatible w/ the more commonly used IV infusion fluids in infusion bags such as:
1. 0.9% NaCl inj
2. D5 inj
3. All combinations of dextrose inj and NaCl inj, containing up to 2.5% dextrose, and 0.45% NaCl
4. Lactated Ringer's inj
5. Baxter Mini-Bag Plus containing 0.9% NaCl inj or D5 inj
Stability
Upon constitution w/ appropriate diluent, the constituted sol may be held for no longer than 30 min prior to transfer and dilution in a suitable infusion bag.
Following dilution of the constituted sol w/ the appropriate diluents, sol in the infusion bags are stable for 12 hrs when stored at room temperature; may also be refrigerated at 2-8°C (36-46°F) for up to 24 hrs; and then should be used w/in 12 hrs of subsequent storage at room temperature.
HOW SUPPLIED
Inj: (Ceftazidime/Avibactam) 2g/0.5g
CONTRAINDICATIONS
Known serious hypersensitivity to the components of Avycaz (ceftazidime and avibactam), avibactam-containing products, or other members of the cephalosporin class.
WARNINGS/PRECAUTIONS
Reserve use in patients who have limited or no alternative treatment options. Decreased clinical response in patients w/ baseline CrCl 30 to ≤50mL/min. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions reported; d/c if an allergic reaction occurs. Cross-sensitivity among β-lactam antibacterials reported; caution in penicillin (PCN) or other β-lactam allergic patients. Clostridium difficile-associated diarrhea (CDAD) reported; may need to d/c if CDAD is suspected or confirmed. Seizures, nonconvulsive status epilepticus, encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia reported, particularly in the setting of renal impairment; adjust dosing based on CrCl. Use in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit and increases the risk of development of drug-resistant bacteria. Caution in elderly. Lab test interactions may occur.
ADVERSE REACTIONS
N/V, constipation, anxiety, abdominal pain, dizziness, increased blood alkaline phosphatase, increased alanine aminotransferase.
DRUG INTERACTIONS
Not recommended w/ probenecid.
PREGNANCY AND LACTATION
Pregnancy: Category B.
Lactation: Caution in nursing.
MECHANISM OF ACTION
Ceftazidime: Cephalosporin; binds to essential PCN-binding proteins. Avibactam: β-lactamase inhibitor; inactivates some β-lactamases and protects ceftazidime form degradation by certain β-lactamases.
PHARMACOKINETICS
Absorption: Administration of variable doses resulted in different parameters. Distribution: Ceftazidime: Plasma protein binding (<10%); Vd=17L; found in breast milk. Avibactam: Plasma protein binding (5.7-8.2%); Vd=22.2L. Elimination: Single Dose: T1/2=3.27 hrs (ceftazidime), 2.22 hrs (avibactam). Multiple Doses: T1/2=2.76 hrs (ceftazidime), 2.71 hrs (avibactam). Ceftazidime: Urine (Approx 80-90%, unchanged). Avibactam: Urine (97%), feces (0.20%).
ASSESSMENT
Assess for hypersensitivity to drug, cephalosporins, PCNs, carbapenems, or other β-lactam antibiotics; renal impairment; pregnancy/nursing status; and possible drug interactions. Perform culture and susceptibility testing.
MONITORING
Monitor for signs/symptoms of hypersensitivity reactions, CDAD, seizures, nonconvulsive status epilepticus, encephalopathy, coma, asterixis, neuromuscular excitability, myoclonia, and other adverse reactions. Monitor CrCl at least daily w/ changing renal function.
PATIENT COUNSELING
Advise that allergic reactions, including serious allergic reactions, may occur and require immediate treatment. Advise that diarrhea is a common problem caused by antibacterial drugs; instruct to contact physician if severe watery or bloody diarrhea develops. Inform that neurological adverse reactions may occur; instruct to inform physician immediately if any neurological signs and symptoms develop. Inform that therapy should only be used to treat bacterial, not viral, infections. Advise to take exactly ud; inform that skipping doses or not completing full course of therapy may decrease effectiveness of therapy and increase bacterial resistance.
How Supplied:
Single-use vial—1, 10
STORAGE
25°C (77°F); excursions permitted between 15-30°C (59-86°F). Protect from light.

责任编辑:admin


相关文章
新型抗生素Zavicefta(CAZ-AVI)被欧盟批准上市
Modacin for injection(头孢他啶注射剂)
新型抗生素Avycaz(ceftazidime/avibactam,CAZ-AVI)获欧盟批准
Avycaz(ceftazidime/avibactam for injection)
Avycaz(ceftazidime-avibactam)复方冻干粉注射剂
新类抗菌药Avycaz(ceftazidime-avibactam)获美国FDA批准
复达欣注射液FORTUM(CEFTAZIDIME)
头孢他啶(CEFTAZIDIME,Fortaz)
头孢他啶注射剂|Fortaz(Ceftazidime Vials)
舒而欣
 

最新文章

更多

· AVYCAZ for Injection(c...
· Modacin for injection(...
· Zeftera Intravenous fo...
· 头孢西丁和葡萄糖注射液...
· Procef(Cefprozil)头孢...
· Panoral Caps(头孢克洛...
· Cefoxitin Injection(头...
· CEFDINIR powder(头孢地...
· MEIACT MS(Cefditoren ...
· 头孢克肟干悬浮Cefspan(...

推荐文章

更多

· AVYCAZ for Injection(c...
· Modacin for injection(...
· Zeftera Intravenous fo...
· 头孢西丁和葡萄糖注射液...
· Procef(Cefprozil)头孢...
· Panoral Caps(头孢克洛...
· Cefoxitin Injection(头...
· CEFDINIR powder(头孢地...
· MEIACT MS(Cefditoren ...
· 头孢克肟干悬浮Cefspan(...

热点文章

更多

· Modacin for injection(...
· AVYCAZ for Injection(c...